Table 1 Baseline patient characteristics in different nephrectomy status patient groups

Total

275 (37.6%)

389 (53.1%)

68 (9.3%)

732 (100.0%)

Gender

0.28

 Male

154 (56.0%)

235 (60.4%)

35 (51.5%)

424 (57.9%)

 Female

121 (44.0%)

154 (39.6%)

33 (48.5%)

308 (42.1%)

Age at diagnosis (years)

Median (25th–75th percentiles)

73.3 (61.9–80.0)

64.0 (57.7–72.6)

62.2 (57.3–72.1)

67.0 (59.6–77.6)

< 0.001

ECOG*

< 0.001

 0

15 (5.5%)

41 (10.5%)

7 (10.3%)

63 (8.6%)

 1

116 (42.2%)

272 (69.9%)

50 (73.5%)

438 (59.8%)

 2

144 (52.4%)

76 (19.5%)

11 (16.2%)

231 (31.6%)

T stage*

0.063

 T1

64 (26.6%)

57 (15.1%)

10 (14.9%)

131 (19.1%)

 T2

48 (19.9%)

49 (13.0%)

12 (17.9%)

109 (15.9%)

 T3

66 (27.4%)

227 (60.1%)

35 (52.2%)

328 (47.8%)

 T4

63 (26.1%)

45 (11.9%)

10 (14.9%)

118 (17.2%)

N stage

0.638

 N0

161 (58.5%)

240 (61.7%)

39 (57.4%)

440 (60.1%)

 N1

114 (41.5%)

149 (38.3%)

29 (42.6%)

292 (39.9%)

Number of metastatic sites

< 0.001

 1

53 (19.3%)

114 (29.3%)

49 (72.1%)

216 (29.5%)

 2

75 (27.3%)

146 (37.5%)

16 (23.5%)

237 (32.4%)

 ≥ 3

147 (53.5%)

129 (33.2%)

3 (4.4%)

279 (38.1%)

Metastatic sites

Distant lymph nodes

90 (32.7%)

99 (25.4%)

6 (8.8%)

195 (26.6%)

< 0.001

 Lungs

192 (69.8%)

247 (63.5%)

17 (25.0%)

456 (62.3%)

< 0.001

 Bone

96 (34.9%)

111 (28.5%)

6 (8.8%)

213 (29.1%)

0.001

 Adrenal gland

53 (19.3%)

70 (18.0%)

17 (25.0%)

140 (19.1%)

0.398

 Liver

75 (27.3%)

51 (13.1%)

5 (7.4%)

131 (17.9%)

< 0.001

 Brain

24 (31.2%)

16 (18.6%)

2 (12.5%)

42 (23.5%)

0.093

Histology *

0.007

 Clear cell carcinoma

90 (79.6%)

335 (90.5%)

58 (89.2%)

483 (88.1%)

 Other

23 (20.4%)

35 (9.5%)

7 (10.8%)

65 (11.9%)

Hemoglobin < LLN*

132 (63.8%)

141 (54.0%)

28 (60.9%)

301 (58.6%)

0.099

CRP > ULN

132 (77.6%)

154 (72.3%)

26 (78.8%)

312 (75.0%)

0.424